TORREY phase 2 study of seralutinib in pulmonary arterial hypertension: Circulating biomarkers of proliferation, inflammation and fibrosis improve with treatment
TORREY phase 2 study of seralutinib in pulmonary arterial hypertension: Circulating biomarkers of proliferation, inflammation and fibrosis improve with treatment
WSPH – June 2024b
Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).
